NO20042146L - Substiuerte 1,4-benzodiazepiner og anvendelse derav - Google Patents
Substiuerte 1,4-benzodiazepiner og anvendelse deravInfo
- Publication number
- NO20042146L NO20042146L NO20042146A NO20042146A NO20042146L NO 20042146 L NO20042146 L NO 20042146L NO 20042146 A NO20042146 A NO 20042146A NO 20042146 A NO20042146 A NO 20042146A NO 20042146 L NO20042146 L NO 20042146L
- Authority
- NO
- Norway
- Prior art keywords
- sup
- sub
- optionally substituted
- cycloalkyl
- aralkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33123501P | 2001-11-13 | 2001-11-13 | |
PCT/US2002/036208 WO2003041715A1 (en) | 2001-11-13 | 2002-11-13 | Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20042146L true NO20042146L (no) | 2004-08-11 |
Family
ID=23293137
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20042146A NO20042146L (no) | 2001-11-13 | 2004-05-25 | Substiuerte 1,4-benzodiazepiner og anvendelse derav |
Country Status (26)
Country | Link |
---|---|
US (2) | US7067512B2 (es) |
EP (1) | EP1443937B1 (es) |
JP (1) | JP4497921B2 (es) |
KR (1) | KR20050044413A (es) |
CN (1) | CN1596114A (es) |
AT (1) | ATE398453T1 (es) |
AU (1) | AU2002340464B2 (es) |
BR (1) | BR0214048A (es) |
CA (1) | CA2466055A1 (es) |
CY (1) | CY1108352T1 (es) |
DE (1) | DE60227185D1 (es) |
DK (1) | DK1443937T3 (es) |
ES (1) | ES2309209T3 (es) |
HR (1) | HRP20040415A2 (es) |
HU (1) | HUP0402003A3 (es) |
IL (1) | IL161692A0 (es) |
MX (1) | MXPA04004500A (es) |
NO (1) | NO20042146L (es) |
NZ (1) | NZ532463A (es) |
PL (1) | PL370176A1 (es) |
PT (1) | PT1443937E (es) |
RU (1) | RU2004118243A (es) |
SI (1) | SI1443937T1 (es) |
UA (1) | UA76798C2 (es) |
WO (1) | WO2003041715A1 (es) |
ZA (1) | ZA200403082B (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040197893A1 (en) * | 2002-10-16 | 2004-10-07 | Carsten Schubert | HDM2-inhibitor complexes and uses thereof |
US20050227932A1 (en) * | 2002-11-13 | 2005-10-13 | Tianbao Lu | Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction |
US7358241B2 (en) * | 2003-01-21 | 2008-04-15 | Thallion Pharmaceuticals, Inc. | Compositions and methods comprising farnesyl dibenzodiazepinones for treating neoplastic cells and conditions |
US7655646B2 (en) * | 2003-01-21 | 2010-02-02 | Thallion Pharmaceuticals, Inc. | Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals |
US7186713B2 (en) | 2003-01-21 | 2007-03-06 | Ecopia Biosciences, Inc. | Farnesyl dibenzodiazepinones and methods of treating cancer using same |
ES2304078B2 (es) * | 2003-07-02 | 2009-09-16 | Gilead Sciences Inc. | Sal de aztreonam-l-lisina y metodos para la preparacion de la misma. |
AU2005272627A1 (en) | 2004-08-13 | 2006-02-23 | Amgen Inc. | Substituted benzofused heterocycles |
KR101331786B1 (ko) | 2004-09-22 | 2013-11-21 | 얀센 파마슈티카 엔.브이. | Mdm2 및 p53간의 상호작용 저해제 |
SI1797115T1 (sl) | 2004-09-28 | 2017-10-30 | Janssen Pharmaceutica N.V. | Bakterijska domena, ki veže ATP sintazo |
US7763604B2 (en) * | 2005-05-16 | 2010-07-27 | Thallion Pharma Ceuticals, Inc. | Methods for administration of a farnesyl dibenzodiazepinone |
AU2006308655B2 (en) * | 2005-11-01 | 2010-09-23 | The Regents Of The University Of Michigan | Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties |
AU2007228782B2 (en) | 2006-03-22 | 2012-09-06 | Janssen Pharmaceutica N.V. | Inhibitors of the interaction between MDM2 and p53 |
DE602007007065D1 (de) | 2006-03-22 | 2010-07-22 | Janssen Pharmaceutica Nv | Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53 |
WO2008014216A1 (en) | 2006-07-28 | 2008-01-31 | St. Jude Children's Research Hospital | Method for treating ocular cancer |
US8470785B2 (en) | 2006-07-28 | 2013-06-25 | St. Jude Children's Research Hospital | Method for treating ocular cancer |
AU2007332493A1 (en) | 2006-12-14 | 2008-06-19 | Daiichi Sankyo Company, Limited | Imidazothiazole derivatives |
TWI539947B (zh) * | 2007-04-09 | 2016-07-01 | 米希爾金尼公司 | 組蛋白去乙醯基酶之抑制劑 |
EA017249B8 (ru) * | 2007-05-10 | 2013-01-30 | Олбани Молекьюлар Рисерч, Инк. | Арил- и гетероарилзамещенные тетрагидробензо-1,4-диазепины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина |
WO2008144981A1 (fr) * | 2007-05-25 | 2008-12-04 | Topharman Shanghai Co., Ltd. | Procédés et intermédiaires pour préparer une 4-acétyl-2,3,4,5-tétrahydro-1h-1,4-benzodiazépine |
CA2934114A1 (en) * | 2007-06-12 | 2008-12-18 | Achaogen, Inc. | Antibacterial agents |
EP2185541B1 (en) | 2007-08-06 | 2015-01-28 | Janssen Pharmaceutica, N.V. | Substituted phenylenediamines as inhibitors of the interaction between MDM2 and p53 |
AR070449A1 (es) * | 2008-02-22 | 2010-04-07 | Otsuka Pharma Co Ltd | Compuesto de benzodiazepina y composicion farmaceutica |
WO2009151069A1 (ja) | 2008-06-12 | 2009-12-17 | 第一三共株式会社 | 4,7-ジアザスピロ[2.5]オクタン環構造を有するイミダゾチアゾール誘導体 |
EA021883B1 (ru) | 2009-02-04 | 2015-09-30 | Янссен Фармацевтика Нв | Производные индола в качестве противораковых агентов |
FR2967072B1 (fr) | 2010-11-05 | 2013-03-29 | Univ Dundee | Procede pour ameliorer la production de virus et semences vaccinales influenza |
CN102321034B (zh) * | 2011-06-07 | 2014-08-13 | 中国人民解放军第二军医大学 | 硫代苯二氮卓类化合物及其作为药物的用途 |
ES2707305T3 (es) | 2012-12-20 | 2019-04-03 | Merck Sharp & Dohme | Imidazopiridinas sustituidas como inhibidores de HDM2 |
CN105693634B (zh) * | 2016-03-17 | 2018-12-11 | 清华大学 | 化合物及其用途 |
US10669242B2 (en) * | 2016-06-10 | 2020-06-02 | Venenum Biodesign, LLC | Clostridium difficile toxin inhibitors |
EP3573644B1 (en) | 2017-01-25 | 2022-03-16 | Sorrento Therapeutics, Inc. | Cell penetrating peptide inhibitors of p53-mdm2 interaction |
CN110317294B (zh) * | 2018-03-30 | 2021-06-18 | 长春理工大学 | 一种三苯胺类温敏荧光聚合物及其制备方法 |
CN111995576A (zh) * | 2020-08-31 | 2020-11-27 | 三峡大学 | 多取代含氮杂环化合物的制备方法 |
TW202345852A (zh) * | 2022-03-16 | 2023-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠雜環類化合物、其製備方法及其在醫藥上的應用 |
CN117263873A (zh) * | 2022-06-15 | 2023-12-22 | 复旦大学 | 1,4-苯二氮䓬类化合物及其在制备抗肿瘤药物中的用途 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5250679A (en) | 1991-10-18 | 1993-10-05 | Genentech, Inc. | Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor |
US5389631A (en) | 1991-10-29 | 1995-02-14 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US5272158A (en) | 1991-10-29 | 1993-12-21 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US5441952A (en) | 1993-04-05 | 1995-08-15 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
EP0755394A1 (en) | 1994-04-15 | 1997-01-29 | Glaxo Wellcome Inc. | A method of inducing cholecystokinin agonist activity using 1,4-benzodiazepine compounds |
US5817751A (en) * | 1994-06-23 | 1998-10-06 | Affymax Technologies N.V. | Method for synthesis of diketopiperazine and diketomorpholine derivatives |
DE19653645A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung |
US6492553B1 (en) * | 1998-01-29 | 2002-12-10 | Aventis Pharamaceuticals Inc. | Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds |
SK10642000A3 (sk) | 1998-01-29 | 2001-07-10 | Aventis Pharmaceuticals Products Inc. | Spôsob prípravy n-[(alifatickej alebo aromatickej)karbonyl)]-2- aminoacetamidovej zlúčeniny a cyklizovanej formy tejto zlúčeniny |
WO2000056721A1 (en) | 1999-03-23 | 2000-09-28 | Axys Pharmaceuticals, Inc. | Solid phase synthesis of benzodiazepine diones |
US6440959B1 (en) * | 1999-04-21 | 2002-08-27 | Hoffman-La Roche Inc. | Pyrazolobenzodiazepines |
MXPA01011052A (es) | 1999-04-30 | 2002-11-22 | Univ Michigan | Aplicaciones terapeuticas de benzodiazepinas pro-apoctoticas. |
WO2001004103A1 (en) | 1999-07-13 | 2001-01-18 | F. Hoffmann-La Roche Ag | Benzazepinones and quinazolines |
US6600016B1 (en) * | 1999-08-24 | 2003-07-29 | Advanced Syntech Llc | Multifunctionalized solid support resins for synthesis of combinatorial libraries and method for using the same |
AU2882801A (en) * | 2000-01-28 | 2001-08-07 | Kaken Pharmaceutical Co., Ltd. | Azepine derivatives |
-
2002
- 2002-11-13 NZ NZ532463A patent/NZ532463A/en not_active IP Right Cessation
- 2002-11-13 DK DK02778828T patent/DK1443937T3/da active
- 2002-11-13 AT AT02778828T patent/ATE398453T1/de active
- 2002-11-13 IL IL16169202A patent/IL161692A0/xx unknown
- 2002-11-13 PT PT02778828T patent/PT1443937E/pt unknown
- 2002-11-13 EP EP02778828A patent/EP1443937B1/en not_active Expired - Lifetime
- 2002-11-13 SI SI200230733T patent/SI1443937T1/sl unknown
- 2002-11-13 BR BR0214048-9A patent/BR0214048A/pt not_active IP Right Cessation
- 2002-11-13 PL PL02370176A patent/PL370176A1/xx not_active Application Discontinuation
- 2002-11-13 US US10/292,876 patent/US7067512B2/en not_active Expired - Fee Related
- 2002-11-13 CA CA002466055A patent/CA2466055A1/en not_active Abandoned
- 2002-11-13 HU HU0402003A patent/HUP0402003A3/hu unknown
- 2002-11-13 DE DE60227185T patent/DE60227185D1/de not_active Expired - Lifetime
- 2002-11-13 CN CNA028239156A patent/CN1596114A/zh active Pending
- 2002-11-13 RU RU2004118243/04A patent/RU2004118243A/ru not_active Application Discontinuation
- 2002-11-13 UA UA20040604569A patent/UA76798C2/uk unknown
- 2002-11-13 AU AU2002340464A patent/AU2002340464B2/en not_active Ceased
- 2002-11-13 ES ES02778828T patent/ES2309209T3/es not_active Expired - Lifetime
- 2002-11-13 WO PCT/US2002/036208 patent/WO2003041715A1/en not_active Application Discontinuation
- 2002-11-13 JP JP2003543602A patent/JP4497921B2/ja not_active Expired - Fee Related
- 2002-11-13 MX MXPA04004500A patent/MXPA04004500A/es active IP Right Grant
- 2002-11-13 KR KR1020047007168A patent/KR20050044413A/ko not_active Application Discontinuation
-
2004
- 2004-04-22 ZA ZA200403082A patent/ZA200403082B/en unknown
- 2004-05-07 HR HR20040415A patent/HRP20040415A2/hr not_active Application Discontinuation
- 2004-05-25 NO NO20042146A patent/NO20042146L/no not_active Application Discontinuation
-
2006
- 2006-03-09 US US11/371,964 patent/US20060148792A1/en not_active Abandoned
-
2008
- 2008-09-17 CY CY20081101010T patent/CY1108352T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
DE60227185D1 (de) | 2008-07-31 |
PT1443937E (pt) | 2008-09-23 |
KR20050044413A (ko) | 2005-05-12 |
ATE398453T1 (de) | 2008-07-15 |
JP4497921B2 (ja) | 2010-07-07 |
US20060148792A1 (en) | 2006-07-06 |
DK1443937T3 (da) | 2008-10-20 |
EP1443937B1 (en) | 2008-06-18 |
US7067512B2 (en) | 2006-06-27 |
CN1596114A (zh) | 2005-03-16 |
BR0214048A (pt) | 2004-10-13 |
HUP0402003A2 (hu) | 2005-02-28 |
HRP20040415A2 (en) | 2005-04-30 |
PL370176A1 (en) | 2005-05-16 |
CY1108352T1 (el) | 2014-02-12 |
ES2309209T3 (es) | 2008-12-16 |
EP1443937A1 (en) | 2004-08-11 |
MXPA04004500A (es) | 2004-08-11 |
SI1443937T1 (sl) | 2009-02-28 |
ZA200403082B (en) | 2005-04-22 |
NZ532463A (en) | 2007-02-23 |
JP2005509005A (ja) | 2005-04-07 |
RU2004118243A (ru) | 2006-01-10 |
IL161692A0 (en) | 2004-09-27 |
HUP0402003A3 (en) | 2005-06-28 |
CA2466055A1 (en) | 2003-05-22 |
US20030109518A1 (en) | 2003-06-12 |
AU2002340464B2 (en) | 2008-03-13 |
WO2003041715A1 (en) | 2003-05-22 |
UA76798C2 (uk) | 2006-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20042146L (no) | Substiuerte 1,4-benzodiazepiner og anvendelse derav | |
SE0400284D0 (sv) | Novel compounds | |
WO2004010949A3 (en) | Compounds active in spinigosine 1-phosphate signaling | |
HRP20020926B1 (en) | Arylmethylamine derivatives for use as tryptase inhibitors | |
DK1678166T3 (da) | Proteinkinaseinhibitorer | |
HRP20070430T3 (en) | (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity | |
NO20053890L (no) | Syntese av 4-amino-2-butenolklorider og anvendelse derav for fremstilling av 3-cyanokinoliner | |
NO20082346L (no) | Hydrazonderivater og anvendelser derav | |
EA200401612A1 (ru) | Противоаллергические средства | |
WO2005092858A3 (en) | Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist | |
DE60130771D1 (de) | Substituierte heterocyclische amide | |
DE602004020730D1 (de) | Pharmazeutisches verfahren und damit hergestellte verbindungen | |
WO2003049690A3 (en) | Hiv integrase inhibitors | |
BR0311960A (pt) | Derivado de 1-[ (indol-3-il) carbonil] piperazina, uso do mesmo e composição farmacêutica | |
NO20060277L (no) | Anvendelse av bisyklo [2.2.1] heptanderivater til fremstilling av nevrobeskyttende farmasoytiske sammensetninger | |
NO20052197L (no) | Fremgangsmate for fremstilling av pyrazol | |
EA200501136A1 (ru) | Триазольные соединения, полезные в терапии | |
NO20064073L (no) | Derivater fra 2H- eller 3H-benzo[e]indazol-1-yl-karbamat, deres fremstilling og terapeutisk anvendelse derav | |
IL182547A0 (en) | 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinolinecarbonitriles for the treatment of ischemic injury | |
DE602004031878D1 (de) | Immunhemmende pyrazolon-verbindungen | |
PL1735274T3 (pl) | Niepeptydowe inhibitory metaloproteinaz macierzy zewnątrzkomórkowej | |
EP1344777A4 (en) | IMIDAZOLE DERIVATIVES, PROCESS FOR PREPARING THEM AND THEIR APPLICATION | |
NO20065156L (no) | Hittil ukjente forbindelser for behandling av hjertearytmi og bruksmetoder | |
EA200000373A2 (ru) | Новые соединения 1-аза-2-алкил-6-арилциклоалкана, способ их получения и содержащие их фармацевтические композиции | |
EP1707560A4 (en) | HYDROXAMIC ACID DERIVATIVE AND THE DERIVATIVE INHIBITOR OF THE GENERATION OF AGE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |